City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest honor bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network, City of Hope's research and treatment protocols advance care throughout the nation. City of Hope is located in Duarte, Calif., just northeast of Los Angeles, and is ranked as one of "America’s Best Hospitals" in cancer and urology by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org.
Here are the latest facts about this institution.

INSTITUTIONAL DISTINCTIONS

• City of Hope is one of 39 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute (NCI).
• City of Hope is a founding member of the National Comprehensive Cancer Network, an alliance of the top 20 cancer centers that defines and sets standards for cancer care nationally.
• The NCI awarded City of Hope a five-year, $15.2 million program project grant to develop innovative therapies for leukemia, lymphoma and myelodysplasia. This is the 25th consecutive year that City of Hope has received federal funding for this program. - City of Hope has been designated an islet cell transplant center by the Juvenile Diabetes Research Foundation (JDRF), one of only 14 institutions in the United States to receive this distinction.
• At any given time, City of Hope conducts more than 300 clinical studies, involving 30 to 40 percent of its eligible patients. The national average is less than 5 percent.
• City of Hope was awarded more than $55 million in research grants and received nearly $98.7 million in revenues from patented technologies in FY2006.

RESEARCH AND TREATMENT MILESTONES

• A growing number of important treatments are based on research pioneered by City of Hope scientists, including the drugs Herceptin, Rituxan and Avastin.
• Millions of people with diabetes worldwide benefit from synthetic human insulin developed through research conducted at City of Hope.
• City of Hope surgeons were among the first to utilize robotic technology for the treatment of cancer, significantly improving the outcomes for patients with prostate cancer and other malignancies.
• City of Hope is the first - and currently only - institution in the world to perform a clinical study using genetically engineered T-cells to recognize and attack glioma, a highly lethal form of brain cancer.
• City of Hope is the first institution in the world to operate two TomoTherapy units, considered the most advanced radiation therapy technology available.
• An early pioneer in bone marrow transplantation, City of Hope has performed more than 7,500 bone marrow and stem cell transplants, and today operates one of the largest, most successful programs of its kind in the world.

RESEARCH QUANTIFIED
One of 39 NCI-designated Comprehensive Cancer Centers

Has performed more than 7,500 bone marrow and stem cell transplants

Awarded more than $55 million in research grants

First institution in the world to operate two TomoTherapy units

Founding member of the National Comprehensive Cancer Network’s top 20 cancer centers that defines and sets standards for cancer care.

Currently conducts more than 300 clinical studies

RECENT RESEARCH BREAKTHROUGHS
New approach to fighting autoimmune diseases
In a first step toward a possible method to offset the ravages of type 1 diabetes and other autoimmune diseases, City of Hope scientists have discovered how a critical component of the immune system, the Tr-cell, functions. This new understanding may help in the design of a strategy to effectively prevent and possibly reverse various autoimmune diseases.

Focusing on cancer stem cells
City of Hope researchers believe that understanding how normal and malignant stem cells are regulated at the molecular level can lead to new therapies targeting cancer stem cells that will increase the chance of a cure. Scientists engaged in stem cell and leukemia biology are focusing on characterizing normal and malignant blood stem cells, identifying molecular events in cancerous transformation and developing new anticancer therapies.

Isolating lung cancer markers
Lung cancer kills more people than breast, prostate and colon cancers combined, yet early detection remains difficult. City of Hope scientists have developed a method for isolating and identifying genes associated with lung cancer. In cells, certain sections of DNA change as cancer develops. City of Hope researchers created a technique that can identify cells undergoing these changes and are developing a test to better predict risk and early diagnosis of the disease.

Breast cancer prevention
Scientists at City of Hope have discovered that chemicals in grape seed extract, in the form of skin, seeds and even red wine, can suppress the production of estrogen, a major player in the development of breast cancer. Grape seed extract can also act specifically upon cancerous breast tissues that produce excess amounts of estrogen. These findings may eventually lead to a preventive therapy that would help both pre- and post-menopausal women at risk for breast cancer.

Fighting brain tumors with neural stem cells
Like an arrow shot at a target, neural stem cells (NSCs) home in on primary invasive tumors in the brain. City of Hope scientists have taken advantage of this natural ability of NSCs, using them as transport vehicles to attack multiple tumor sites in a model of melanoma metastases to the brain. The approach resulted in a 70 percent reduction in the tumor volume following treatment. Researchers believe NSCs hold great promise for therapies for primary and metastatic brain tumors.

UNPARALLELED RESOURCES

• City of Hope created a new model for rapidly translating innovations from the research lab to the clinical setting with its Center for Biomedicine & Genetics, recognized as the nation’s premier academic biologic manufacturing facility. In addition to being designated as the National Institutes of Health’s (NIH) National Gene Vector Laboratory for the production of plasmid DNA for all NIH-sponsored investigators, the center provides researchers everywhere with the widest array of biologics manufacturing expertise.
• City of Hope was designated one of only 10 federally funded islet cell resource centers responsible for processing and distributing islet cells to transplant programs around the country. Islet cell transplantation is an innovative therapy for people with type 1 diabetes.

EXPANSION EFFORTS

• The Arnold and Mabel Beckman Foundation recently awarded City of Hope $20 million to fund construction of a new cancer immunotherapeutics and tumor immunology building. When completed, the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics and Tumor Immunology will provide a self-contained and integrated research environment where novel immunotherapeutic approaches to cancer treatment will be conceived, developed and refined.
• A gift from the Sheri & Les Biller Family Foundation will create a new center at City of Hope to assist patients and families facing cancer and other life-threatening diseases. The 3,000 square foot Les & Sheri Biller Patient & Family Resource Center will be a uniquely comprehensive model that will integrate and expand a wide range of patient support services, including health education, psychological services, healing arts programs, and end-of-life and bereavement care programs.

HOW CITY OF HOPE ADDS UP

• City of Hope received full accreditation by the Joint Commission on Accreditation of Healthcare Organizations, the nation’s most widely recognized health care accrediting body.
• The Chronicle of Philanthropy and The Nonprofit Times featured City of Hope in their annual surveys of the nation’s top nonprofits.

For more information about City of Hope, please go to www.cityofhope.org

For Clinical Trials Online ^SM, City of Hope's electronic clinical trials database, go to http://clinicaltrials.coh.org

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A City of Hope Protocol for Collecting, Banking and Release of Human Biological Materials for Research
• A Compassionate Use Study of Methylnaltrexone in Patients with Opioid-Induced Side Effects
• A Multi-Center Phase III Double-Blind Clinical Trial to Evaluate the Efficacy of Mycophenolate Mofetil added to Prednisone plus Cyclosporine or Tacrolimus for Treatment of Newly Diagnosed Chronic Graft Vs Host Disease
• A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresctable StageIII or Stage IV Melanoma
• A Pharmacokinetic and Pharmacogenomic Study of Patients with High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide
• A Phase 1 Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multipe Myeloma
• A Phase 1b/2 Study of AMG 655 in Combination with Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
• A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenecity and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched, Related Hematpoietic Cell Transplant (HCT)
• A Phase I Clinical Trial of Vorinostat in Combination with Decitabine in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
• A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus
• A Phase I Dose Escalation Study of Peptide Vaccines with Activity Against Human Cytomegalovirus
• A Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination with Erlotinib in Non-Small Cell Lung Cancer in Patients
• A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor in Healthy High-Risk Post-Menopausal Women
• A Phase I Safety and Pharmacokinetic Study of IT-101 in the Treatment of Advanced Solid Tumors
• A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine
• A Phase I Study of Alefacept (Amevive) in the Treatment of Cutaneous-T-Cell Lymphoma and Peripheral T-Cell NHL
• A Phase I Study of Bortezomib and Temozolomide in Patients with Refractory Solid Tumors
• A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation
• A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-Cell Non-Hodgkin’s Lymphoma
• A Phase I Study of Yttrium-90 Labeled Humanized Anti-CEA M5A Antibody in Patients with CEA Producing Advanced Malignancies
• A Phase I Trial of PS-341 in Combination with Topotecan in Advanced Solid Tumor Malignancies
• A Phase I Trial of Radiommunotherapy (Y90 cT8.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver
• A Phase I Trial of Re-Irradiation by Helical Tomotherapy in Combination with Oxaliplatin in Patients with Previously Irradiated Recurrent Head and Neck Cancer
• A Phase I, Open-Label, Dose Escalation First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics and Pharmacodynamics of GSK923295 in Subjects with Refractory Cancers
• A Phase I/II Study of Nelfinavir in Liposarcoma
• A Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma
• A Phase II Multicenter Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma
• A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
• A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
• A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
• A Phase II Multicenter, Open Label , Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non Squamous Non Small Cell Lung Cancer
• A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B–Cell Non–Hodgkin Lymphoma Using Zevalin®, Fludarabine and Melphalan
• A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma
• A Phase II Study of Rituximab-ABVD in Classical Hodgkin's Lymphoma
• A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation
• A Phase II Study or Oral LBH589 in Adult Patients with Mutiple Myeloma Who Have Received at Least Two Prior Lines of Therapy and Whose Disease is Refractory to the Most Recent Line of Therapy
• A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients with Advanced Renal Cell Carcinoma
• A Phase II, Multicenter, Prospective, Observational, Open-Label Study to Evaluate the Safety and Efficacy of AMD3100 (240ug/kg) Added to a G-CSF Mobilization Regimen in Poor Mobilizing Adult Patients Who Have Previously Failed Stem Cell Collections or Collection Attempts
• A Phase II, Open Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects with Stage III Melanoma
• A Phase II, Open Label, Non Compariative, International, Multicenter Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients with Advanced BRCA-1 or BRCA2 Associated Breast Cancer
• A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment with the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients with Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy. Iogen Iden, Inc. Protocol #307940/106-20
• A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid-Refractory Acute GVHD (Protocol #280)
• A Pilot Feasibility Study of Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Temozolomide
• A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
• A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
• A Pilot Study to Determine the Reliability of Telomerase RNA Detection in the Expressed Prostatic Secretion of Men Undergoing Prostatic Biopsy in Confirming Cancer Diagnosis
• A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bone Sarcomas
• A Random Assignment Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouacil (mDCF) versus Parent DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
• A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally at a Dose of 800mg Daily or Doxorubicin Administered Intravenously at a Dose of 60mg/m2 Every 3 Weeks in Patients with Unsectable, Locally Advanced or Metastatic Hepatocellular Carcinoma
• A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First Line Therapy for Metastatic Renal Cell Cancer (Renal Effect Trial)
• A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
• A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combiniation with AMG 386 or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney
• A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants
• A Randomized, Open-Label, Phase II/III Multicenter Study of High Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM and Autologous Transplantation with Auto CD34+ HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
• A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non Small Cell Lung Cancer
• A Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
• A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere (Yittrium-90 Glass Microspheres): A HDE Treatment Use Protocol
• ACOSOG Z4032: A Randomzied Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller
• Acquisition of Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Donors for use as Support Cells in Ex-Vivo T Cell Expansions
• Acquisition of Peripheral Blood and Bone Marrow to Support Laboratory Correlative Studies
• Acquisition of Peripheral Blood or Marrow Cells for Laboratory Study
• Age-Related Changes in Nanoparticle Albumin Bound (nab) Paclitaxel Pharmacokinetics and Pharmacodynamics
• Allogeneic Stem Cell Transplantation for Patients with Hematological Malignancies Using Multiple Unrelated Cord Blood Units
• Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Helical Tomotherapy, Melphalan, and Fludarabine in Acute Myelogenous Leukemia
• AMG 531, 20030213: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
• An International, Randomized, Controlled Trial of Immune-Tolerance Induction
• An Open Label Phase I/II Study of Safety and Efficacy of Perifosine and Bortezomib with or without Dexamethasone for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib
• An Open Label, Single Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
• An Open-Label, Phase II, Extension Study of MDX-060 with Gemcitabine in Patients Relapsed or Refractory Hodgkin's Disease Previously Treated in Protocol MDX060-05
• An Open-label, Randomized, Multicenter, Phase II Study of MDX 060 in Combination with Gemcitabine, MDX-060 in Combination with Dexamethasone, and Gemcitabine Monotherapy in Patients with Relapsed or Refractory Hodgkin's Disease
• Androgen Deprivation and Localized Radiotherapy to Metastases in Patients with Oligometastatic Hormone - Sensitive Prostate Cancer
• Biomarkers, Breast Density, and Risk Reduction Perspectives
• Bladder Cancer Database
• Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
• BMT CTN 0201: A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors
• BMT CTN 0301: Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia
• BMT CTN 0303: A Single Arm, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+Enriched, T Cell Depleted Peripheral Blood Stem Cells Isolated by The CliniMACS System in The Treatment of Patients With AML in First or Second Morphologic Complete Remission
• BMT CTN 0402: A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-Versus-Host-Disease (GVHD)Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation
• CA180004: A Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
• CA180114: A Phase II Clinical Trial of Dasatinib in Patients with Metastatic Pancreatic Cancer
• CALGB 100104/ECOG 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
• CALGB 80101: Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
• Cervical Cancer Survivorship among African American and Latina Survivors
• Childhood Cancer Survivor Study
• CIBMRT 05-DCB: A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
• COG AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia
• COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia
• COG AALL03B1: Classification of Acute Lymphoblastic Leukemia
• COG AALL03N1: Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia
• COG ALTE03N1: Key Adverse Events After Childhood Cancer
• COG ALTE03N1: Key Adverse Events After Childhood Cancer
• COG ANBL0032: Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue
• COG AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy- a Phase III Intergroup Study
• Comparison of Cytochrome P4503A4 Activity in Fed and Fasting Healthy Subjects
• Compassionate Treatment of Malignant Neuroendocrine Tumors with Radioactive MIBG
• Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation, AnorMED Protocol, AMD3100-CUP001
• CT Follow Up for Detection of Second Tobacco-Related Cancer
• CTSU/ECOG E2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Resected Renal Cell Carcinoma
• CTSU/ECOG: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
• CTSU/NCCTG:N0147 A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or w/o Cetuximab (C225 After Curative Resection for Patients with Stage III Colon Cancer
• Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Phase II Study Protocol
• Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase III Study to Determine Safety and Efficacy
• Delineation of Causative Mutations in Hemophilia B
• Detection of Cellular/Immune Responses to MITF in Normal Subjects and Patients with Melanoma
• ECOG: E1Y97: Mapping Interactive Cancer Susceptibility Loci
• Effect of Differentiation Status and Tissue Specificity of Graft Cells on Graft-Versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation
• EMR 62206-015: A Phase I Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics. Biological and Clinical Activity of EMD 273066 Administered with Low-Dose Cyclophosphamide to Subjects with Epithelial Cell Adhesion Molecule (EpCAM) Positive Advance Cancers
• Erectile Dysfunction Recovery in Men age
• Evaluation of BCL-XL Specific Immunity
• Evaluation of the use of Poxvirus Vaccines to Stimulate P53 Specific Immunity
• EXTEND (Eltrombopag eXTENded Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, with Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study
• Feasibility Evaluation of a Modified Blood Glucose Control Algorithm
• Forward Image Guided Ductoscopy for Early Cancer Screening
• Fungal Antigens and Antifungal Response
• Genetic Epidemiology of Non-Hodgkin's Lymphoma (NHL)
• Hematopoietic Cell Transplantation for Hematological Malignancies: Neuropsychological Function after Hematopoietic Cell Transplantation
• Hemophilia Inhibitor Genetics Study
• Hemophilic Genotype, Inhibitors and Response to Immune Tolerance
• High Dose Chemotherapy and Combination anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma
• Hollywood Arthritis Samples
• Identification of Genes and Pathways in Tumorigenesis and Progression of Malignant Melanoma
• Immune Studies in Chronic Myelogenous Leukemia (CML)
• Immunologic Studies From Normal Bone Marrow Donors and Volunteers for the Study of CMV
• Immunological and Genetic Analysis of Autoinflammatory Genes In Fibromyalgia
• Immunophenotype and Function of Bone Marrow-Infiltrating Lymphocytes in Patients with Myeloid Leukemias
• Individualized Risk Information System (IRIS) for BRCA Carriers
• Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
• Innovative Underserved Community-Based Cancer Risk Screening
• Innovative Underserved Community-Based Cancer Risk Screening
• Invasive Fungal Infections (IFI) Surveillance Initiative: Protocol #001
• Islet After Kidney Transplantation (IAK) in Patient with Type 1 Diabetes Using a Sirolimus/Tacrolimus based Immunosuppressive Regimen
• Islet Transplantation Alone (ITA) in Patients with Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
• Liposarcoma Tissue Procurement Protocol
• Liver Surgery and Ablation in Older Versus Younger Adults: Longitudinal Impact on Functional Status and Quality of Life
• Long Term Follow Up after Prostate Cancer
• Long Term Follow-up Clinic for Survivors of Childhood Cancer
• Long-Term Follow Up of Recipients of Gene Transfer Research at City of Hope
• Long-Term Follow Up of Recipients of Gene Transfer Research at City of Hope
• Long-Term Follow-Up Following Bone Marrow Transplantation: Core C of the Program Project Grant (P01 CA30206), Hematopoietic Cell Transplantation for Hematologic Malignancies
• Longitudinal Molecular Profiling of Islet Recipient's Blood
• Mechanisms of Response and Resistance to STI571 in CML
• Medarex MDX010-20: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
• Molecular Epidemiology of Human Disease
• Molecular Genetic Studies in Cancer Patients and Their Relatives
• Molecular Mechanisms of Hyperglycemia and Diabetes Induced Monocyte Activation
• Molecular Pathogenesis of Acute Leukemia and Myelodysplasia
• Molecular Pathogenesis of Therapy-Related Leukemia
• Monitoring Islet Graft Integrity with Bidirectional Pyrophosphorolysis- Activated Polymerization Allele-Specific Amplification (BI-PAP-A) Assays
• Multicenter Evaluation of Breast Cancer Patients and Outcomes of Care within the National Comprehensive Cancer Network (NCCN)
• Multicenter Evaluation of Colon/Rectal Cancer Patterns and Outcomes of Care Within the National Comprehensive Cancer network (NCCN)
• Multicenter Evaluation of Non-Hodgkins Lymphoma patterns and Outcomes of Care Within the National Comprehensive Cancer Network (NCCN)
• Multiple Myeloma Research Consortium Inc. Ancillary Tissue Collection Study
• NCIC CTG MAP.3 A Phase III Randomized Study of Exemestane vs Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
• NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients With Node-Negative Breast Cancer
• NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (A1) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
• NSABP Protocol B-39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
• NSABP Protocol C-10: A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor
• NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum
• Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Volunteer Donors for Use in T Cell Program
• Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Mantle Cell Lymphoma Patients in Remission for Use in T Cell Program
• Optical Biosensor for the Early Detection of Breast Cancer
• OSI Radiant: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR Positive Tumors
• Ovarian Cancer and Quality of Life Intervention
• Passport for Care: Implementation in Multiple Institutions
• PaTK01: A Phase I Study of ADV-TK Therapy in Combination with Surgery and Chemoradiation for Pancreas
• Phase I Multicenter, Dose Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, A Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients with Advanced B-Lymphoid Malignancies
• Phase I-II Study of Escalating Doses of Large Field Image Guided Intensity Modulated Radiation Therapy (IMRT) using Helical Tomotherapy in Combination with Etoposide (VP-16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients with Poor Risk Acute Lymphocytic Leukemia (ALL)
• Phase I-II Trial of ZD1839 (IRESSA), Trastuzumab (Herceptin), and Docetaxel (Taxotere) in Patients with erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
• Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined with Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation(HSCT) for Patients with Advanced Myeloid Malignancies
• Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias (Wyeth No. 3160A1-200-US)
• Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Mephalan and Carboplatin, Thiotepa, and Cyclophosphamide (STAMP V)+/-Trastuzumab followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer
• Phase II Trial Utilizing Idarubicin in Combination with High-Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia
• PHI-16: Phase I Trial of 5-Fluoro-2'-deoxycytidine with Tetrahydrouridine
• PHI-47 NCI#6581: Phase I Trial of R115777 (NSC 702818) In Relapsed, Refractory or High-Risk Myeloid Leukemia
• PHI-48 NCI#6777: Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemia
• PHI-50 NCI#6432: A Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group
• PHI-52 NCI#7225: A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine)in the Treatment of Advanced Solid Tumors
• PHI-53 NCI#7251: A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies
• PHI-55 NCI#7427: A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors
• PHI-57 NCI# 7689: Phase I Trial of GTI2040 in Relapsed, Refractory, or High Risk Leukemia and Myelodysplasia
• PHI-59 NCI #8057: Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
• PHI-61 NCI#7967: A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies
• PHII-059 NCI#1312: Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
• PHII-18: Randomized Phase II Study of Cytoxan, Thiotepa, and Carboplatin (STAMP V) with or without Pamidronate in Patients with High-Risk Primary Breast Cancer
• PHII-57 NCI#7003: A Phase II Study of Bortezomib (PS-341) for Patients with Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features
• PHII-65 NCI #7103: A Phase II Study of AZD2171 (NSC #732208)in Patients with Malignant Mesothelioma
• PHII-66 NCI#7028: A Phase II Study of BAY 43-9006 for Patients with Imatinib-and Sunitinib Resistant Gastrointestinal Stromal Tumor
• PHII-70 NCI #7077: Randomized Phase II Trial of Sequential versus Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443) in Previously Treated Non-Small Cell Lung Cancer
• PHII-73 NCI #7518: A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS
• PHII-75, NCI #7435: A Phase I/II Study of E7389 Halichondrin B Analog (NSC 707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
• PHII-76, NCI #7533; A Phase II Study of VEGF Trap (NSC 724770) in Patients with Recurrent or Metastatic Transitional Carcinoma of the Urothelium
• PHII-77 NCI#7522: A Phase II Study Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stage IV Melanoma
• PHII-80 PHL-051 NCI #7502: A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas
• PHII-81 NCI#7129: A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
• PHII-82-NCI #7863: Randomized Phase II Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
• PHII-83 NCI #7792: A Phase II Trial of Dasatinib (BMS354825) in Advanced Hepatocellular Carcinoma
• PHII-86 NCI #7925: A Phase 2 Study of AZD6244 in Relapsed or Refractory AML
• PHII-87 NCI #7703: Phase I/II Study of a Combination of Suberolyanilde Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer
• Pilot Study of Dose Adjustment of Vinorelbine in Patients with Varying Degree of Liver Dysfunction
• Pilot Study of High-Dose Chemotherapy with Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors
• Pre-Surgical Detection of Colorectal Carcinomas Using 123Iodine-Labeled cT84.66 Diabody Antibody Fragments to Carcinoembryonic Antigen (CEA)
• Pre-Surgical EPS Biomarkers as Predictors of Recurrence
• Procurement and Research Evaluation of Human Blood and Tissues for Detection of Occult Malignancies Using the Polymerase Chain Reaction (PRCR)
• Prospective Chart Review for Data Inclusion into Sentinel Node Working Group
• Prostate Cancer Database
• Prostate Cancer Outcomes by Race and Treatment Site
• Protocol for a Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
• Protocol H6Q-MC-S022 A Phase Ib Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)
• Protocol PR1-104 - Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study
• Quality of Life Assessment in Childhood Cancer Survivors
• Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed By Abraxane/Carboplatin (ACAC) +/- Trastuzumab As Neoadjuvant Therapy for Patients with Stage I-III Breast Cancer
• Randomized Pilot Trial of Oral Cyclophosphamide versus Oral Cyclophosphamide with Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• Reducing Barriers to Pain and Fatigue Management
• Reducing the Burden of Breast Cancer Among African American and Latina Survivors
• Role of Glutathione Peroxidase and Helicobacter Spp. in Inflammatory Bowel Disease and Colonic Cancer
• RTOG 0320: A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non Small Cell Lung Cancer and 1-3 Brain Metastases
• RTOG 0418: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT)to the Pelvis +/- Chemotherapy for Post-Operative Patients with Either Endometrial or Cervical Carcinoma
• RTOG 0433 (NCIC CTG SC.20) A Phase III International Randomized Trial of Single Versus Multiple Fractions For Re-Irradiation of Painful Bone Metastases
• RTOG 0522: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
• RTOG 0525: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma
• RTOG 0529: A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal
• SARC-009: A Phase II Trial of Dasantinib in Advanced Sarcoma
• Sister Survivor: African American Breast Cancer Coalition
• Standardized Nursing Intervention Protocol for HCT Patients
• Studies of Prevalence and Immunity to KB and JC Viruses in Normal Volunteers
• SWOG 9007: Cytogenetic Studies In Leukemia Patients
• SWOG 9007: Cytogenetic Studies In Leukemia Patients
• SWOG 9007: Cytogenetic Studies In Leukemia Patients
• SWOG 9346: Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III
• SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
• SWOG E1697: Phase III Randomized Study of Four Weeks of High Dose IFN-a2b in Stage T3 - T4 or N1 (microscopic) Melanoma
• SWOG S0221: Phase III Trial of Continuous Schedule AC + G Vs. Every 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
• SWOG S0226: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
• SWOG S0229: A Randomized Trial Assessing the Effects of Exercise on Patients with Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy
• SWOG S0333: A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy
• SWOG S0350: Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (Pegs) in Peripheral T-Cell Non-Hodgkin's Lymphoma
• SWOG S0410: Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin's Disease (A BMT Study)
• SWOG S0421: Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
• SWOG S0424: Molecular Epidemiology Case-Series Study of NSCLC in Smoking and Non-Smoking Women and Men
• SWOG S0433: Iodine-131 Labeled Monoclonal Antibody (I-131 Tositumomab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B Cell NHL; A Phase II Study
• SWOG S0434: A Phase II Trial of Bay 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma
• SWOG S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
• SWOG S0528: Phase I Study Evaluating the Combination of Lapatinib (GW572016 NSC-727989, IND-75,093) and Everolimus(RAD001; NSC-733504; IND 75, 093) in Patients with Advanced Solid Tumors
• SWOG S9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary
• T2005-003: A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
• Tandem High-Dose Therapy with Melphalan and Total Marrow Irradiation (TMI) with Peripheral Blood Progenitor Cell Support and Dexamethasone and Thalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial
• The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients with Breast Cancer
• The High-Dose Aldesleukin (IL-2) Select Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Metastatic Renal Cell Carcinoma
• The Impact of Functional Strain on Psychological and Familial Functioning and Access to Follow-up Care Among Asian American Breast Cancer Survivors
• The Relationship Between Coping, Gender and Psychological Adaptation in People with Lung Cancer
• The Role of Gene Expression in Predicting Response to Chemoradiation in Advanced Rectal Cancers
• Tissue and Blood Library Establishment for Molecular, Biochemical, and Histologic Study of Breast Diseases
• Trialnet Natural History Study of the Development of Type I Diabetes
• UCD #171/GSK #104241: Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination with Vinorelbine in Advanced Solid Tumors
• Understanding the Barriers and Facilitators to Adherence to Oral Chemotherapy in Youth with Acute Lymphoblastic Leukemia
• Universal Data & Serum Specimen Collection System for Hemophilia

For more information, please contact:

New Patient Services
City of Hope
1500 E. Duarte Rd.
Duarte, CA 91010 USA
Phone: 800-826-HOPE (4673)
Fax: